With drug pricing becoming a hot-button issue in recent years, the spotlight has focused on cost effectiveness models as a means of reducing health care spending, and pharmaceutical spending in particular. Precision’s Jacquelyn Chou argues that the current cost effectiveness model is too narrow, and identifies additional elements of value that should be included to provide a better voice for patients in the science, rather than serving as a cost-containment tool.
Read the full article here!